ArriVent BioPharma, Inc. (AVBP) Stock Forecast & Price Target

Compare

47 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AVBP Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

ArriVent

BioPharma, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AVBP Stock 12 Month Forecast

Average Price Target

$39.83

▲(131.97% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for ArriVent BioPharma, Inc. in the last 3 months. The average price target is $39.83 with a high forecast of $45.00 and a low forecast of $33.00. The average price target represents a 131.97% change from the last price of $17.17.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","46":"$46","22.75":"$22.8","30.5":"$30.5","38.25":"$38.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$33.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,22.75,30.5,38.25,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.84,21.775384615384617,23.71076923076923,25.646153846153847,27.58153846153846,29.516923076923078,31.45230769230769,33.387692307692305,35.323076923076925,37.25846153846154,39.19384615384615,41.12923076923077,43.06461538461539,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.84,21.377692307692307,22.915384615384614,24.45307692307692,25.99076923076923,27.528461538461535,29.066153846153846,30.603846153846153,32.14153846153846,33.67923076923077,35.216923076923074,36.75461538461538,38.29230769230769,{"y":39.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.84,20.852307692307694,21.864615384615384,22.876923076923077,23.88923076923077,24.90153846153846,25.913846153846155,26.926153846153845,27.93846153846154,28.950769230769232,29.963076923076922,30.975384615384616,31.987692307692306,{"y":33,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.69,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.41,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.15,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.5,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.73,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.78,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.64,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.89,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$45.00

Average Price Target$39.83

Lowest Price Target$33.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sam Slutsky

LifeSci Capital

$37

Buy

115.49%

Upside

Reiterated

09/09/25

Promising Market Position and Strong Clinical Results Lead to Buy Rating for ArriVent BioPharma, Inc.

Yigal Nochomovitz

Citi

$33

Buy

92.20%

Upside

Reiterated

09/09/25

ArriVent BioPharma Buy Rating: Strong Clinical Data and Strategic Positioning Highlight PotentialWe expect AVBP shares to appreciate further over the next ~90 days as investors better appreciate the potential of the EGFR PACC market segment on the heels of updated positive Ph1b data and newly announced plans to initiate a Ph3 trial in PACC mutations, as well as anticipation of Ph3 FURVENT data in early 2026.Arrivent Biopharma Inc. (AVBP.O) 09 Biopharma Inc.

Soumit Roy

JonesTrading

$45

Buy

162.09%

Upside

Reiterated

08/15/25

ArriVent BioPharma, Inc.: Promising Future with Strong Financials and Key Data Releases Justifying Buy Rating

Robert Burns

H.C. Wainwright

$40→$42

Buy

144.61%

Upside

Reiterated

08/12/25

ArriVent Biopharma price target raised to $42 from $40 at H.C. WainwrightArriVent Biopharma price target raised to $42 from $40 at H.C. Wainwright

Michael Schmidt

Guggenheim

$45

Buy

162.09%

Upside

Reiterated

08/11/25

Guggenheim Sticks to Their Buy Rating for ArriVent BioPharma, Inc. (AVBP)Maintaining our Buy rating and $45/shr PT.

Kalpit Patel

B. Riley Securities

$37

Buy

115.49%

Upside

Reiterated

07/21/25

ArriVent BioPharma, Inc. (AVBP) Receives a Buy from B.Riley Financial

Corinne Johnson

Goldman Sachs

―

Buy

―

Reiterated

07/18/25

We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.

Jeff Jones

Oppenheimer

$39→$44

Buy

156.26%

Upside

Reiterated

06/24/25

ArriVent Biopharma price target raised to $44 from $39 at OppenheimerArriVent Biopharma price target raised to $44 from $39 at Oppenheimer

Kaveri Pohlman

Clear Street

$32

Buy

86.37%

Upside

Initiated

06/24/25

ArriVent Biopharma initiated with a Buy at Clear StreetArriVent Biopharma initiated with a Buy at Clear Street

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sam Slutsky

LifeSci Capital

$37

Buy

115.49%

Upside

Reiterated

09/09/25

Promising Market Position and Strong Clinical Results Lead to Buy Rating for ArriVent BioPharma, Inc.

Yigal Nochomovitz

Citi

$33

Buy

92.20%

Upside

Reiterated

09/09/25

Soumit Roy

JonesTrading

$45

Buy

162.09%

Upside

Reiterated

08/15/25

ArriVent BioPharma, Inc.: Promising Future with Strong Financials and Key Data Releases Justifying Buy Rating

Robert Burns

H.C. Wainwright

$40→$42

Buy

144.61%

Upside

Reiterated

08/12/25

ArriVent Biopharma price target raised to $42 from $40 at H.C. WainwrightArriVent Biopharma price target raised to $42 from $40 at H.C. Wainwright

Michael Schmidt

Guggenheim

$45

Buy

162.09%

Upside

Reiterated

08/11/25

Guggenheim Sticks to Their Buy Rating for ArriVent BioPharma, Inc. (AVBP)Maintaining our Buy rating and $45/shr PT.

Kalpit Patel

B. Riley Securities

$37

Buy

115.49%

Upside

Reiterated

07/21/25

ArriVent BioPharma, Inc. (AVBP) Receives a Buy from B.Riley Financial

Corinne Johnson

Goldman Sachs

―

Buy

―

Reiterated

07/18/25

We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.

Jeff Jones

Oppenheimer

$39→$44

Buy

156.26%

Upside

Reiterated

06/24/25

ArriVent Biopharma price target raised to $44 from $39 at OppenheimerArriVent Biopharma price target raised to $44 from $39 at Oppenheimer

Kaveri Pohlman

Clear Street

$32

Buy

86.37%

Upside

Initiated

06/24/25

ArriVent Biopharma initiated with a Buy at Clear StreetArriVent Biopharma initiated with a Buy at Clear Street

Stocks with the Highest Top Analyst Consensus in the General Sector

xxx

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ArriVent BioPharma, Inc.

1 Month

xxx

Success Rate

8/12 ratings generated profit

Average Return

+2.00%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +2.00% per trade.

3 Months

xxx

Success Rate

7/12 ratings generated profit

Average Return

+5.82%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +5.82% per trade.

1 Year

Robert BurnsH.C. Wainwright

Not Ranked

Success Rate

4/12 ratings generated profit

Average Return

-9.05%

reiterated a buy rating 2 months ago

Copying Robert Burns's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -9.05% per trade.

2 Years

xxx

Success Rate

2/12 ratings generated profit

Average Return

-15.69%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 16.67% of your transactions generating a profit, with an average return of -15.69% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AVBP Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AVBP has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AVBP average Analyst price target in the past 3 months is 39.83.

Each month's total comprises the sum of three months' worth of ratings.

AVBP Financial Forecast

AVBP Earnings Forecast

Next quarter’s earnings estimate for AVBP is -$0.79 with a range of -$0.88 to -$0.66. The previous quarter’s EPS was -$0.90. AVBP beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 83.33% of the time in the same period. In the last calendar year AVBP has Outperformed its overall industry.

No data currently available

AVBP Sales Forecast

Next quarter’s sales forecast for AVBP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVBP beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 60.00% of the time in the same period. In the last calendar year AVBP has Preformed in-line its overall industry.

AVBP Stock Forecast FAQ

What is AVBP’s average 12-month price target, according to analysts?

Based on analyst ratings, ArriVent BioPharma, Inc.’s 12-month average price target is 39.83.

What is AVBP’s upside potential, based on the analysts’ average price target?

ArriVent BioPharma, Inc. has 131.97% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AVBP a Buy, Sell or Hold?

ArriVent BioPharma, Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is ArriVent BioPharma, Inc.’s price target?

The average price target for ArriVent BioPharma, Inc. is 39.83. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $45.00 ,the lowest forecast is $33.00. The average price target represents 131.97% Increase from the current price of $17.17.

What do analysts say about ArriVent BioPharma, Inc.?

ArriVent BioPharma, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of AVBP?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

ArriVent BioPharma, Inc. (AVBP) Stock Forecast & Price Target

AVBP Analyst Ratings

AVBP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering ArriVent BioPharma, Inc.

AVBP Analyst Recommendation Trends

AVBP Financial Forecast

AVBP Earnings Forecast

AVBP Sales Forecast

AVBP Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts